Kevin D. Seibert (ChemEngr'90)
2026 Distinguished Engineering Alumni Award recipient
Kevin Seibert is a technical VP with Eli Lilly and Co. and holds a BS in chemical engineering from the University of Colorado Boulder, as well as MS and PhD degrees in chemical engineering from the University of Michigan. He has over 30 years’ experience working in small and medium molecule syntheses for both Merck and Eli Lilly. Seibert has been responsible for the process development and optimization of many early and late-phase products and led the technology transfer, validation and launch of several marketed compounds.
Seibert has also led initiatives for developing enhanced regulatory filings in support of the ICH QbD efforts, driving efficiency and consistency in marketed compound regulatory filings worldwide. Most recently, Seibert led the chemistry and engineering teams responsible for the process development and commercialization of Eli Lilly’s Zepbound/Mounjaro. Seibert led the expert teams with the conception and implementation of a strategy for synthesizing synthetic peptides using a novel manufacturing platform employing both continuous manufacturing and real-time release approaches. This novel manufacturing platform has led to significant improvements in manufacturing efficiency, environmental impact and end product quality, with broad applicability to Lilly’s growing synthetic peptide portfolio.
Seibert is a fellow of the American Institute of Chemical Engineers, where he has served as chair of the PD2M forum, driving the application of chemical engineering principles to discovery, development and manufacturing within the pharmaceutical industry. Seibert served as chair of the Drug Substance Leadership Group for the IQ Consortium, and as a member of the Board of Directors for the Emerging Technologies Consortium.
Seibert is passionate about mentoring, teaching and providing opportunities for scientists to thrive, and is author/co-author of more than 80 technical publications, book chapters and presentations. He holds three patents on various pharmaceutical processes.